Zycolchin Tablet contains Colchicine 0.5 mg, an alkaloid used primarily for the treatment and prophylaxis of gout flares and familial Mediterranean fever (FMF). Colchicine exerts its therapeutic effect by disrupting microtubule polymerization, thereby inhibiting neutrophil motility and activity, which reduces inflammation caused by urate crystal deposition. Zycolchin is indicated for the management of acute gout attacks, prevention of recurrent gouty arthritis, and reduction of FMF-related inflammatory episodes. It is also utilized off-label in certain inflammatory conditions such as pericarditis. The tablet is administered orally, with dosage adjusted based on clinical response and patient tolerance to minimize adverse effects. Common side effects include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain; these are dose-dependent and can be mitigated by dose adjustment. Caution is advised in patients with renal or hepatic impairment, as well as those on concomitant medications that may interact with colchicine metabolism, including CYP3A4 inhibitors and P-glycoprotein inhibitors, due to increased risk of toxicity. Zycolchin should be used under medical supervision, with careful monitoring for signs of colchicine toxicity, which can be severe. It is contraindicated in patients with known hypersensitivity to colchicine and in those with significant bone marrow suppression.